464152-37-2 Usage
General Description
Methyl 2-(2-methoxypyridin-4-yl)acetate is a chemical compound that belongs to the ester group. It is derived from the combination of methyl, methoxypyridin, and acetate functional groups. Methyl 2-(2-methoxypyridin-4-yl)acetate has various applications in the pharmaceutical and agrochemical industries. It is commonly used as an intermediate in the synthesis of organic compounds and as a building block in the production of pharmaceuticals and agrochemicals. Additionally, it may also be used as a flavoring agent in the food industry. Methyl 2-(2-methoxypyridin-4-yl)acetate is known for its diverse uses and versatile nature in different industrial applications.
Check Digit Verification of cas no
The CAS Registry Mumber 464152-37-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,6,4,1,5 and 2 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 464152-37:
(8*4)+(7*6)+(6*4)+(5*1)+(4*5)+(3*2)+(2*3)+(1*7)=142
142 % 10 = 2
So 464152-37-2 is a valid CAS Registry Number.
464152-37-2Relevant articles and documents
SPIRO COMPOUNDS AS MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF
-
Page/Page column 94, (2021/12/31)
Described herein are compounds of Formula I and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.
COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES AS GLUTAMINASE INHIBITORS FOR TREATING CANCERS THEREOF
-
Page/Page column 130-131; 133, (2014/06/11)
Provided are compounds of formula (I), wherein X, Y, Z, W, m, n, o, p, R1, R2 and R6 are defined as in the description. Pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof are also provided.
